Walgreens partners with Orlando Health to provide coordinated and expanded healthcare services
DEERFIELD, Ill. — Walgreens and Orlando Health, a comprehensive not-for-profit healthcare organization based in Orlando, Fla., on Wednesday announced a clinical collaboration that will provide coordinated and expanded healthcare services, while improving patient access to high-quality, convenient and affordable care throughout Central Florida.
"In today’s healthcare landscape, these types of innovative coordinated care programs are vitally important to help ensure patients have access to the quality care they need," stated Jeffrey Kang, Walgreens SVP health and wellness services and solutions. "With our expansive retail footprint, diverse portfolio of healthcare assets and proven success in collaborating with others in the medical community, Walgreens is uniquely positioned to bridge critical gaps in care and improve patient outcomes, furthering our mission to help patients get, stay and live well."
The collaboration and services offered will foster greater access to care with Healthcare Clinics at select Walgreens offering evening and weekend hours, convenient locations and online appointment scheduling; better coordination of care for Orlando Health patients with Healthcare Clinic providers for acute, chronic and preventive services; direct communication between Orlando Health physicians and Healthcare Clinic nurse practitioners to facilitate care coordination and sharing of patient information; and increasing patient awareness regarding Orlando Health services, as well as information and awareness of Healthcare Clinic services, including routine screening, monitoring, immunizations, and clinic locations and hours.
Walgreens and Orlando Health also are exploring opportunities to share electronic medical records, with the goal of developing read-only access to real-time patient medical information. This level of coordination also could include creating online or call center appointment scheduling technology to further increase patient access to services.
"A key tenet of our mission is to improve the health of the individuals in the communities we serve, and by utilizing new approaches, such as this relationship with Walgreens, we’ll be able to better reach and treat the patients of Central Florida," said Wayne Jenkins, president of Orlando Health Physician Partners. "This relationship represents the type of collaborative strategies that we view as essential in the emerging healthcare environment. We’re confident that by working together, our two organizations can help ensure that patients are receiving the best care, in the best locations, as well as a truly seamless care experience."
Orlando Health has six wholly-owned hospitals and two partnership hospitals throughout Central Florida, a skilled nursing facility, Physician Associates, one of the largest multi-specialty physician practices in central Florida, consisting of more than 90 physicians in more than 20 locations, along with more than 2,500 affiliated physicians. The clinical collaboration includes 13 Healthcare Clinic locations at select Walgreens in nearby cities, including Orlando, Kissimmee, Apopka, Winter Springs, Clermont, Lake Buena Vista, Lake Mary, Winter Park and Windermere, Fla.
"Orlando Health is an established healthcare leader in Central Florida, and its integrated approach to improving the community’s health is a great strategic fit for Walgreens and our mission," Kang said.
CHPA applauds Delaware, 29th state to adopt NPLEx
WASHINGTON — The Consumer Healthcare Products Association on Wednesay applauded Delaware Rep. Rebecca Walker, the Delaware legislature and Gov. Jack Markell for passing and signing House Bill 130, an anti-methamphetamine bill. With Governor Markell’s signature, Delaware becomes the 29th state to adopt the pseudoephedrine real-time, stop-sale blocking system known as the National Precursor Log Exchange.
“With Governor Markell’s signature on this important legislation, Delaware joins the majority of states throughout the country in its use of illegal sales blocking technology,” stated Scott Melville, CHPA president and CEO. “In addition to Delaware, 28 other states have chosen to adopt the NPLEx system because it provides an exceptional resource to law enforcement and retailers, while ensuring that law-abiding consumers continue to have access to the cold and allergy medicines they know and trust," he said. "More than 18 million American families rely on safe and effective medicines containing pseudoephedrine for relief from their symptoms."
NPLEx is a tool that allows retailers and pharmacists to block unlawful attempted purchases of cold and allergy medicines containing PSE that exceed daily or monthly limits established by the 2005 federal Combat Methamphetamine Epidemic Act. NPLEx empowers retailers and law enforcement officials with the ability to track and block illegal sales of products containing PSE at the counter.
Prior to the implementation of NPLEx, retailers had to manually record PSE purchases in a hand-written logbook. The system is provided at no charge to the state.
Pure Encapsulations launches four specialty supplement formulas to support brain function
SUDBURY, Mass. — Pure Encapsulations on Tuesday launched its PureSynapse product line, including SeroPlus, DopaPlus, NeuroPure and Amino Replete, four specialty formulas to support emotional health, memory and behavior that was formulated with James Greenblatt, an author and lecturer who is dedicated to integrative psychiatry.
“As we begin to better understand nutritional deficiencies and toxic environmental chemicals that interfere with brain function, we are better able to provide safe and effective support for mental health,” Greenblatt stated.
SeroPlus is designed to support serotonin levels, lessening occasional stress and maintaining healthy eating behaviors. DopaPlus promotes healthy dopamine levels for daily mental sharpness and memory. NeuroPure provides enhanced support for overall emotional well-being by boosting both serotonin and dopamine levels. And Amino Replete delivers a blend of free-form amino acids required for the synthesis of neurotransmitters and neuropeptides.
Additional products will be introduced to the series in the fall of 2013, the company stated.